A Brussels bureaucrat / @EU_Health and pharma policy / accessibility availability affordability of medicines / health systems resilience/ RTâ endorsement /đ
Have you ever wondered how new medicines are developed, approved and priced? This explainer outlines the long journey from the discovery of a new drug to when it becomes available on the NHS.
The coronavirus is not yet very well researched â so restrictions are based on preliminary findings.
sylvain giraudThe science behind coronavirus restrictions The coronavirus is not yet very well researched â so restrictions are based on preliminary findings
86d
Experts say itâs normal for levels of antibodies to drop after clearing an infection, and that they represent just one arm of the immune response against a virus.
On 22 October, President Charles Michel sent out the third issue of his newsletter, in which he informs citizens about the activities of the European Council. This time the President focuses on boosting European action to beat the virus.
1
sylvain giraud"We need a Union of tests and vaccines," says EU President Michel in his newsletter
86d
Executives, board members, and related investment funds have made fortunes from the dizzying rise in their companies' stock prices before a single vaccine has proven safe and effective or a game-changing treatment has been approved.
sylvain giraudDrug company insiders are profiting handsomely from the worldâs desperate hope for a COVID-19 vaccine
86d
Democrats and Republicans alike can agree on one thing: prescription drug prices are unacceptably high. Predictably, however, we cannot seem to agree on a proper solution to this urgent issue.